Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies
Research output: Contribution to journal › Review › Research › peer-review
Standard
Exploring the Relationship between Anti-VEGF Therapy and Glaucoma : Implications for Management Strategies. / Daka, Qëndresë; Špegel, Nina; Atanasovska Velkovska, Makedonka; Steblovnik, Tjaša; Kolko, Miriam; Neziri, Burim; Cvenkel, Barbara.
In: Journal of Clinical Medicine, Vol. 12, No. 14, 4674, 2023.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Exploring the Relationship between Anti-VEGF Therapy and Glaucoma
T2 - Implications for Management Strategies
AU - Daka, Qëndresë
AU - Špegel, Nina
AU - Atanasovska Velkovska, Makedonka
AU - Steblovnik, Tjaša
AU - Kolko, Miriam
AU - Neziri, Burim
AU - Cvenkel, Barbara
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023
Y1 - 2023
N2 - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.
AB - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.
KW - anti-VEGF
KW - elevated intraocular pressure
KW - glaucoma
U2 - 10.3390/jcm12144674
DO - 10.3390/jcm12144674
M3 - Review
C2 - 37510790
AN - SCOPUS:85166354352
VL - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 14
M1 - 4674
ER -
ID: 366508825